免疫グロブリンの世界市場：将来予測 (2022年～2030年)

世界の免疫グロブリンの市場規模は、予測期間中 (2022年～2030年) に6.87%のCAGRで成長すると予測されています。市場の主な促進要因として、自己免疫疾患や免疫不全疾患の発生率の上昇や、高齢者人口の増加、研究開発 (R&D) 活動の活発化などが挙げられます。

地域別に見ると、アジア太平洋が最も急速に成長すると見込まれています。

当レポートでは、世界の免疫グロブリンの市場について分析し、主な促進・抑制要因、市場規模の動向見通し (過去3年間・今後9年間分)、セグメント別および地域別の詳細動向、競合情勢、主要企業のプロファイル (企業概要、主要製品／サービス、SCOT分析、事業戦略ほか) などについて調査しております。

目次

第1章 調査範囲・手法

第2章 エグゼクティブサマリー

第3章 市場力学

• 主な市場促進要因
  • 高齢者人口の増加
  • 免疫不全疾患と自己免疫疾患の有病率
  • 研究開発活動の増大
• 主な市場抑制要因
  • 治療費の高さ
  • 副作用のリスクの高さ

第4章 主要な分析

• COVID-19が免疫グロブリン市場に与える影響
• 市場の主な動向
• ポーターのファイブフォース分析
• 市場機会マトリックス
• ベンダー情勢
• 主な購入基準
• 規制の枠組み

第5章 製品別の市場

• IGG
• IGA
• IGM
• IGE
• IGD

第6章 送達方法別の市場

• 免疫グロブリン静注療法
• 皮下免疫グロブリン
• 筋肉内免疫グロブリン

第7章 用途別の市場

• 低ガンマグロブリン血症
• 慢性炎症性脱髄性多発神経障害 (CIDP)
• 原発性免疫不全症
• 重症筋無力症
• 多巣性運動ニューロパチー
• 特発性血小板減少性紫斑病（ITP）
• 炎症性筋疾患
• 特定抗体欠損症
• ギランバレー症候群
• その他の用途

第8章 流通チャネル別の市場

• 病院薬局
• 専門薬局
• その他の流通チャネル

第9章 エンドユーザー別の市場

• 病院・クリニック
• 在宅医療

第10章 地域分析

• 北米
  • 市場規模・推計
  • 主要な成長実現要因
  • 主な課題
  • 主要企業
  • 国別の分析
• 欧州
• アジア太平洋
• 他の国々 (RoW)

第11章 競合情勢

• 主要戦略の展開動向
  • 企業合併・買収 (M&A)
  • 製品の発売と開発
  • 事業提携、契約
  • 事業拡大・売却
• 企業プロファイル
  • ADMA BIOLOGICS
  • BIO PRODUCTS LABORATORY
  • BIOTEST AG
  • CHINA BIOLOGIC PRODUCTS INC
  • CSL BEHRING
  • GRIFOLS SA
  • KAMADA LTD
  • KEDRION BIOPHARMA
  • LFB GROUP
  • OCTAPHARMA AG
  • PFIZER INC
  • SANQUIN PLASMA PRODUCTS BV
  • SHANGHAI RAAS BLOOD PRODUCTS CO LTD
  • SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED

LIST OF TABLES

• TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN
• TABLE 2: REGULATORY FRAMEWORK
• TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 5: GLOBAL IGG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 6: GLOBAL IGG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 7: GLOBAL IGA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 8: GLOBAL IGA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 9: GLOBAL IGM MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 10: GLOBAL IGM MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 11: GLOBAL IGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 12: GLOBAL IGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 13: GLOBAL IGD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 14: GLOBAL IGD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 17: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 18: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 19: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 20: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 21: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 22: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 25: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 26: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 27: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 28: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 29: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 30: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 31: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 32: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 33: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 34: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 35: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 36: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 37: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 38: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 39: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 40: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 41: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 42: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 43: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 44: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 45: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 46: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 47: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 48: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 49: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 50: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 51: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 52: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 53: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 54: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 55: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 56: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 57: GLOBAL HOMECARE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 58: GLOBAL HOMECARE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 59: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 60: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 61: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 62: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 63: LEADING PLAYERS OPERATING IN NORTH AMERICA IMMUNOGLOBULIN MARKET
• TABLE 64: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 65: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 66: LEADING PLAYERS OPERATING IN EUROPE IMMUNOGLOBULIN MARKET
• TABLE 67: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 68: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 69: LEADING PLAYERS OPERATING IN ASIA-PACIFIC IMMUNOGLOBULIN MARKET
• TABLE 70: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
• TABLE 71: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
• TABLE 72: LEADING PLAYERS OPERATING IN REST OF WORLD IMMUNOGLOBULIN MARKET
• TABLE 73: LIST OF MERGERS & ACQUISITIONS
• TABLE 74: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
• TABLE 75: LIST OF PARTNERSHIPS & AGREEMENTS
• TABLE 76: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

• FIGURE 1: KEY MARKET TRENDS
• FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 3: OPPORTUNITY MATRIX
• FIGURE 4: VENDOR LANDSCAPE
• FIGURE 5: KEY BUYING CRITERIA
• FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021
• FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)
• FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)
• FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)
• FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)
• FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)
• FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021
• FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
• FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
• FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
• FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021
• FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)
• FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)
• FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)
• FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)
• FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)
• FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)
• FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)
• FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)
• FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)
• FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)
• FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021
• FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)
• FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)
• FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)
• FIGURE 31: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
• FIGURE 32: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)
• FIGURE 33: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)
• FIGURE 34: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
• FIGURE 35: UNITED STATES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 36: CANADA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 37: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
• FIGURE 38: UNITED KINGDOM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 39: GERMANY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 40: FRANCE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 41: SPAIN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 42: ITALY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 43: NORDIC COUNTRIES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 44: REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 45: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
• FIGURE 46: CHINA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 47: JAPAN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 48: INDIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 49: SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 50: INDONESIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 51: THAILAND IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 52: VIETNAM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 53: AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 54: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 55: REST OF WORLD IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)
• FIGURE 56: LATIN AMERICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
• FIGURE 57: MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

KEY FINDINGS

The global immunoglobulin market is anticipated to rise with a CAGR of 6.87% across the forecast years of 2022 to 2030. The market's growth is strengthened by the increasing incidence of autoimmune disorders as well as immunodeficiency diseases, the rise in the geriatric populace, and the growing research and development activities.

MARKET INSIGHTS

Immunoglobulins are characterized as antibodies that are produced naturally by the body's immune system. They primarily help fight diseases and infections. These glycoprotein molecules are generated by plasma cells and also act as a pivotal component of the immune response of the body.

The rise in the geriatric population across the world is a leading factor expected to fuel the global immunoglobulin market growth over the forecasted years. As an individual ages, their immune system tends to deteriorate and responds relatively slower. This factor significantly increases the risk of sickness.

Moreover, the loss of adaptive immunity entailing older age not only makes a person more vulnerable to infections but also reactivates dormant pathogens that were formerly suppressed. As a result, the senior population is at a higher risk of an increased incidence of immunodeficiency diseases as well as the severity of certain infections. Hence, the growth in the elderly is set to augment the prevalence of age-related diseases, subsequently increasing the need for immunoglobulin products for their treatment.

REGIONAL INSIGHTS

The global immunoglobulin market growth assessment comprises the evaluation of North America, Europe, Asia-Pacific, and Rest of World. The Asia-Pacific is expected to be the fastest-growing region during the forecast years. The regional market's growth is mainly ascribed to the surging prevalence of different types of diseases, the increasing elderly population, and the surge in research and development.

COMPETITIVE INSIGHTS

The competitive rivalry within the global immunoglobulin market is intense and is anticipated to remain high during the forecast period. Furthermore, the presence of numerous leading market players across various regions facilitates a higher level of competition since the industry is fragmented. Some of the key players operating in the market are Pfizer Inc, Kamada Ltd, LFB Group, etc.

Our report offerings include:

• Explore key findings of the overall market

• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

• Market Segmentation cater to a thorough assessment of key segments with their market estimations

• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

• 1.1. STUDY OBJECTIVES
• 1.2. SCOPE OF STUDY
• 1.3. METHODOLOGY
• 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

• 2.1. MARKET SIZE & ESTIMATES
• 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

• 3.1. KEY DRIVERS
  • 3.1.1. GROWTH IN GERIATRIC POPULATION
  • 3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
  • 3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
• 3.2. KEY RESTRAINTS
  • 3.2.1. HIGH COST OF THERAPY
  • 3.2.2. HIGH RISK OF SIDE EFFECTS

4. KEY ANALYTICS

• 4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
• 4.2. KEY MARKET TRENDS
• 4.3. PORTER'S FIVE FORCES ANALYSIS
  • 4.3.1. BUYERS POWER
  • 4.3.2. SUPPLIERS POWER
  • 4.3.3. SUBSTITUTION
  • 4.3.4. NEW ENTRANTS
  • 4.3.5. INDUSTRY RIVALRY
• 4.4. OPPORTUNITY MATRIX
• 4.5. VENDOR LANDSCAPE
• 4.6. KEY BUYING CRITERIA
  • 4.6.1. SOURCE
  • 4.6.2. APPLICATION
  • 4.6.3. EPITOPE
  • 4.6.4. VALIDATION
• 4.7. REGULATORY FRAMEWORK

5. MARKET BY PRODUCT

• 5.1. IGG
• 5.2. IGA
• 5.3. IGM
• 5.4. IGE
• 5.5. IGD

6. MARKET BY MODE OF DELIVERY

• 6.1. INTRAVENOUS IMMUNOGLOBULIN
• 6.2. SUBCUTANEOUS IMMUNOGLOBULIN
• 6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7. MARKET BY APPLICATION

• 7.1. HYPOGAMMA GLOBULINEMIA
• 7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
• 7.3. PRIMARY IMMUNODEFICIENCY DISEASES
• 7.4. MYASTHENIA GRAVIS
• 7.5. MULTIFOCAL MOTOR NEUROPATHY
• 7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
• 7.7. INFLAMMATORY MYOPATHIES
• 7.8. SPECIFIC ANTIBODY DEFICIENCY
• 7.9. GUILLAIN-BARRE SYNDROME
• 7.10. OTHER APPLICATIONS

8. MARKET BY DISTRIBUTION CHANNEL

• 8.1. HOSPITAL PHARMACY
• 8.2. SPECIALTY PHARMACY
• 8.3. OTHER DISTRIBUTION CHANNELS

9. MARKET BY END-USER

• 9.1. HOSPITALS & CLINICS
• 9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

• 10.1. NORTH AMERICA
  • 10.1.1. MARKET SIZE & ESTIMATES
  • 10.1.2. KEY GROWTH ENABLERS
  • 10.1.3. KEY CHALLENGES
  • 10.1.4. KEY PLAYERS
  • 10.1.5. COUNTRY ANALYSIS
    • 10.1.5.1. UNITED STATES
    • 10.1.5.2. CANADA
• 10.2. EUROPE
  • 10.2.1. MARKET SIZE & ESTIMATES
  • 10.2.2. KEY GROWTH ENABLERS
  • 10.2.3. KEY CHALLENGES
  • 10.2.4. KEY PLAYERS
  • 10.2.5. COUNTRY ANALYSIS
    • 10.2.5.1. UNITED KINGDOM
    • 10.2.5.2. GERMANY
    • 10.2.5.3. FRANCE
    • 10.2.5.4. SPAIN
    • 10.2.5.5. ITALY
    • 10.2.5.6. NORDIC COUNTRIES
    • 10.2.5.7. REST OF EUROPE
• 10.3. ASIA-PACIFIC
  • 10.3.1. MARKET SIZE & ESTIMATES
  • 10.3.2. KEY GROWTH ENABLERS
  • 10.3.3. KEY CHALLENGES
  • 10.3.4. KEY PLAYERS
  • 10.3.5. COUNTRY ANALYSIS
    • 10.3.5.1. CHINA
    • 10.3.5.2. JAPAN
    • 10.3.5.3. INDIA
    • 10.3.5.4. SOUTH KOREA
    • 10.3.5.5. INDONESIA
    • 10.3.5.6. THAILAND
    • 10.3.5.7. VIETNAM
    • 10.3.5.8. AUSTRALIA
    • 10.3.5.9. REST OF ASIA-PACIFIC
• 10.4. REST OF WORLD
  • 10.4.1. MARKET SIZE & ESTIMATES
  • 10.4.2. KEY GROWTH ENABLERS
  • 10.4.3. KEY CHALLENGES
  • 10.4.4. KEY PLAYERS
  • 10.4.5. REGIONAL ANALYSIS
    • 10.4.5.1. LATIN AMERICA
    • 10.4.5.2. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

• 11.1. KEY STRATEGIC DEVELOPMENTS
  • 11.1.1. MERGERS & ACQUISITIONS
  • 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
  • 11.1.3. PARTNERSHIPS & AGREEMENTS
  • 11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
• 11.2. COMPANY PROFILES
  • 11.2.1. ADMA BIOLOGICS
  • 11.2.2. BIO PRODUCTS LABORATORY
  • 11.2.3. BIOTEST AG
  • 11.2.4. CHINA BIOLOGIC PRODUCTS INC
  • 11.2.5. CSL BEHRING
  • 11.2.6. GRIFOLS SA
  • 11.2.7. KAMADA LTD
  • 11.2.8. KEDRION BIOPHARMA
  • 11.2.9. LFB GROUP
  • 11.2.10. OCTAPHARMA AG
  • 11.2.11. PFIZER INC
  • 11.2.12. SANQUIN PLASMA PRODUCTS BV
  • 11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
  • 11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
  • 11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED